...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Therapeutic advances in endocrinology and metabolism. >Diagnosing and managing diabetic somatic and autonomic neuropathy
【24h】

Diagnosing and managing diabetic somatic and autonomic neuropathy

机译：诊断和管理糖尿病的躯体和自主神经病

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

The diagnosis and management of diabetic neuropathy can be a major challenge. Late diagnosis contributes to significant morbidity in the form of painful diabetic neuropathy, foot ulceration, amputation, and increased mortality. Both hyperglycaemia and cardiovascular risk factors are implicated in the development of somatic and autonomic neuropathy and an improvement in these risk factors can reduce their rate of development and progression. There are currently no US Food and Drug Administration (FDA)-approved disease-modifying treatments for either somatic or autonomic neuropathy, as a consequence of multiple failed phase III clinical trials. While this may be partly attributed to premature translation, there are major shortcomings in trial design and outcome measures. There are a limited number of partially effective FDA-approved treatments for the symptomatic relief of painful diabetic neuropathy and autonomic neuropathy.
机译：糖尿病性神经病的诊断和治疗可能是一项重大挑战。晚期诊断会以糖尿病性神经病变，足部溃疡，截肢和增加死亡率的形式显着增加发病率。高血糖症和心血管危险因素均涉及躯体和自主神经病的发展，这些危险因素的改善可降低其发展和进展速度。由于多次失败的III期临床试验的结果，目前尚无美国食品和药物管理局（FDA）批准的针对躯体或自主神经病变的疾病缓解疗法。尽管这可能部分归因于过早的翻译，但是审判设计和结果评估方法存在重大缺陷。有限的部分有效的FDA批准的疗法可缓解糖尿病性神经病和自主神经病的症状。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号